1. Inactivated vaccines reduce the risk of liver function abnormality in NAFLD patients with COVID-19: a multi-center retrospective studyResearch in context
- Author
-
Zhixue Chen, Wenqing Tang, Nana Feng, Minzhi Lv, Fansheng Meng, Huibin Wu, Yitong Zhao, Huajie Xu, Yuxin Dai, Jindan Xue, Jingya Wang, Anjun Xu, Beilin Zhang, Dejie Chu, Yuqin Li, Dejun Wu, Ling Dong, Si Zhang, and Ruyi Xue
- Subjects
COVID-19 ,Nonalcoholic fatty liver disease ,Inactivated SARS-CoV-2 vaccine ,Liver function abnormality ,Direct bilirubin ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Abnormal liver function was frequently observed in nonalcoholic fatty liver disease (NAFLD) patients infected with SARS-CoV-2. Our aim was to explore the effect of SARS-CoV-2 inactivated vaccines on liver function abnormality among NAFLD patients with COVID-19. Methods: The multi-center retrospective cohort included 517 NAFLD patients with COVID-19 from 1 April to 30 June 2022. Participants who received 2 doses of the vaccine (n = 274) were propensity score matched (PSM) with 243 unvaccinated controls. The primary outcome was liver function abnormality and the secondary outcome was viral shedding duration. Logistic and Cox regression models were used to calculate the odds ratio (OR) and hazard ratio (HR) for the outcomes. Sensitivity analysis was conducted to assess robustness. Findings: PSM identified 171 pairs of vaccinated and unvaccinated patients. Liver function abnormality was less frequent in the vaccinated group (adjusted OR, 0.556 [95% CI (confidence interval), 0.356–0.869], p = 0.010). Additionally, the vaccinated group demonstrated a lower incidence of abnormal bilirubin levels (total bilirubin: adjusted OR, 0.223 [95% CI, 0.072–0.690], p = 0.009; direct bilirubin: adjusted OR, 0.175 [95% CI, 0.080–0.384], p
- Published
- 2024
- Full Text
- View/download PDF